U.S.-first peptide evidence and policy desk
Primary-source answers for people and professional teams navigating peptide evidence, FDA policy, compounding, and commercial risk.
No protocols. No sourcing. No gray-market promotion.
Consumers need clear evidence and better clinician questions. Operators need regulatory status, commercial implications, and a defensible next step.
Plain-English status pages, evidence labels, meaningful alerts, and questions to take to a licensed clinician.
Explore the consumer watchlist →For professionalsSource-backed briefs and tailored monitoring for clinics, telehealth, pharmacies, labs, advisors, and investors.
See the founding pilot →A committee vote, safety notice, or enforcement letter can look decisive while leaving the real operating status unchanged. Peptide Evidence Watch separates the event from its legal effect.
Status correction · 17 Aug 2026
What changed
FDA’s July briefing proposed not adding BPC-157 free base or acetate to the Section 503A Bulks List. The advisory committee then reviewed the substances, but its advice is non-binding and FDA says a final determination follows completed review.
United States
FDA cited poor characterization, insufficient effectiveness evidence for ulcerative colitis, limited safety information, and unresolved immunogenicity risk. The FDA meeting page does not currently post a final agency action.
Canada
Its April 2026 advisory says “research use only” labelling does not make affected products legal or exempt from regulatory requirements.
Operator action
Evidence before interpretation
FDA, Health Canada, Federal Register, safety alerts, enforcement, and official meeting materials.
Separate approvals, recommendations, proposals, warnings, and commercial-policy changes.
State the likely operator impact, unresolved questions, and required professional review.
Attach publication dates, direct source links, and a visible update history.
Five operator teams only
A 30-day, $250 founding pilot for qualified clinic, pharmacy, lab, advisory, and investment teams. You receive one weekly brief, a tailored watchlist, and a direct feedback loop with the publisher.